[7]
1. Yamazaki M, Straus FH, Robinson MG, Takeda T, Hashizume K, DeGroot LJ: Adenovirus-mediated tumor-specific combined gene therapy using herpes simplex virus thymidine/ganciclovir system and murine interleukin 12 enhanced antitumor activity against medullary thyroid carcinoma. Cancer Gene Ther. 11: 8-15, 2004
2. Takeda T, Inaba H, Yamazaki M, Kyo S, Miyamoto T, Suzuki S, Ehara T, Kakizawa T, Hara M, DeGroot LJ, Hashizume K: Tumor-specific gene therapy for undifferentiated thyroid carcinoma utilizing the telomerase reverse transcriptase promoter. J Clin Endoclinol Metab 88: 3531-3538, 2003
3. Yamazaki M, Zhang R, Straus FH, Messina M, Robinson BG, Hashizume K, DeGroot LJ. Effective gene therapy for medullary thyroid carcinoma using recombinant adenovirus inducing tumor-specific expression of interleukin-12. Gene Ther 9: 64-74, 2002.
4. Takeda T, Yamazaki M, Minemura K, Imai Y, Inaba H, Suzuki S. Miyamoto T, Ichikawa K, Kakizawa T, DeGroot LJ, Hashizume K: A tandemly repeated thyroglobulin core promoter has potential to enhance efficacy for tissue-specific gene therapy for thyroid carcinomas. Cancer Gene Ther. 9: 864-874, 2002
5. Takeda T, Nagasawa T, Miyamoto T, Minemura K, Hashizume K, DeGroot L.J: Quantitative analysis of DNA binding affinity and dimerization properties of wild type and mutant thyroid hormone receptor b1. Thyroid 10: 11-18, 2000
6. Takeda T, Suzuki S, Liu R-T, DeGroot L.J: Triiodothyroacetic acid has unique potential for therapy of resistance to thyroid hormone. J Clin Endocrinol Metab. 80:2033-2040, 1995
